Broker tips: Hikma, Drax, TT Electronics
24th Aug 2016 13:53
(ShareCast News) - Hikma Pharmaceuticals' shares have been maintain as 'hold' by Numis, with a target price of 2660p, following the company's surprise profit warning earlier in August and its interim numbers out on Wednesday. In the six months to end-June, Hikma's core revenue rose to $882m, from $7
Read moreHikma Pharmaceuticals maintained as 'Hold' by Numis with 2660p price target
24th Aug 2016 13:25
(ShareCast News) - Hikma Pharmaceuticals' shares have been maintain as 'Hold' by Numis, with a target price of 2660p, following the company's surprise profit warning earlier in August and its interim numbers out on Wednesday. In the six months to end-June, Hikma's core revenue rose to $882m, from $7
Read moreHikma H1 operating profit drops but FY revenue guidance reiterated
24th Aug 2016 07:48
(ShareCast News) - Hikma Pharmaceuticals reported a jump in first-half revenues but a drop in operating profit, as it reiterated its full-year revenue guidance. In the six months to the end of June, core revenue rose to $882m from $709m, but operating profit slipped to $176m from $204m due to a lowe
Read moreFTSE 100 movers: Housebuilders lead equities higher
23rd Aug 2016 13:58
(ShareCast News) - The FTSE 100 rose 0.66% to 6,873.69 points in afternoon trade on Tuesday, with housebuilders topping the London index. Persimmon led housebuilders higher after reporting a better-than-expected jump in first half profits. Pre-tax profit rose 29% to £352.3m in the six months to 30 J
Read moreWednesday preview: Hikma Pharmaceuticals reports interims in wake of profit warning
23rd Aug 2016 12:29
(ShareCast News) - Hikma Pharmaceuticals reports its interim results on Wednesday just weeks after surprising the market with a profit warning. In a first half trading update on 4 August, the drug maker said it expected core operating profit of its generics arm to be between $30m and $40m, compared
Read moreBroker tips: Johnston Press, Direct Line, Hikma Pharmaceuticals
4th Aug 2016 11:01
(ShareCast News) - Johnston Press shares plunged on Thursday as Numis placed its rating and target price 'under review' after the company swung to a first half loss. For the 26 weeks to 2 July, the company posted a statutory pre-tax loss of £183.7m versus a £2.2m profit the year before, as it booked
Read moreCiti downgrades Hikma Pharmaceuticals after company´s pre-announcement
4th Aug 2016 09:59
(ShareCast News) - Analysts at Citi downgraded their recommendation on shares of Hikma Pharmaceuticals in the wake of the company´s trading update which was issued after the close of trading in London on 3 August. Hikma flagged new drug approvals were arriving more slowly than expected and the phasi
Read moreHikma Pharmaceuticals warns generic drug delays will lower profit
4th Aug 2016 09:12
(ShareCast News) - Shares in Hikma Pharmaceuticals plummeted on Thursday after the drugmaker's overnight warning that delays to new US generic products would lower profits. In a trading update for the first six months of the year that was released almost an hour after the London stock market closed
Read moreHikma says colchicine regulatory approval upheld in US Court of Appeals
21st Jul 2016 09:11
(ShareCast News) - Hikma Pharmaceuticals on Thursday said the regulatory approval of its gout medication colchicine has been upheld. The US Court of Appeals for the District of Columbia Circuit affirmed an earlier decision of the US District Court for the District of Columbia, finding in fa
Read moreHikma Pharmaceuticals launches generic cancer tablets in US
20th Jul 2016 11:54
(ShareCast News) - Hikma Pharmaceuticals said its wholly-owned US affiliate, West-Ward Pharmaceuticals has launched generic cancer treatment tablets in the US. The Capecitabine tablets, which are the generic equivalents to Xeloda tablets, are indicated for adjuvant treatment in patients with Dukes'
Read moreDirectors dealings: Hikma chief dips back in after gout victory
27th Jun 2016 14:24
(ShareCast News) - Hikma Pharmaceuticals chief executive Said Darwazah has further boosted his stake in the company with a huge £3.3m purchase of shares. Darwazah, whose father set up Hikma in 1978, showed his confidence in the company with a purchase of 150,000 shares at a price of 2,200p, al
Read moreFTSE quarterly review confirms raft of changes to 100 and 250 indices
2nd Jun 2016 08:00
(ShareCast News) - Hikma Pharmaceuticals' promotion to the FTSE 100 index was confirmed after the latest quarterly review was announced overnight, while demoted blue chip Inmarsat was joined in the FTSE 250 by three recently floated finance groups CYBG, CMC Markets and Metro Bank plus several others
Read moreInmarsat set for FTSE demotion in quarterly review
31st May 2016 10:19
(ShareCast News) - Satellite communications company Inmarsat could be pushed out of the FTSE 100 by Hikma Pharmaceuticals in June, according to the FTSE Russell. Changes from the latest quarterly review of the FTSE 100, to be announced on Wednesday, will take place on Friday 17 June. Earlier this m
Read moreUS court dismisses Takeda's claims against Hikma Pharmaceuticals
19th May 2016 13:49
(ShareCast News) - The US District Court for the district of Delaware has dismissed claims made by Takeda Pharmaceuticals USA against Hikma Pharmaceuticals and its wholly-owned US subsidiary West-Ward Pharmaceutical. Takeda had alleged the infringement of patents covering methods of use of its colch
Read moreHikma paints positive picture as investors gather
12th May 2016 12:07
(ShareCast News) - Multinational pharmaceutical group Hikma Pharmaceuticals was holding its annual general meeting in London on Thursday, where it was set to confirm a solid start to the year and reiterate its overall guidance for 2016. The FTSE 250 firm continued to expect full-year group revenue i
Read more